Education
About Us
Working with TipRanks
Follow Us
Cybin (TSE:CYBN)
NEO-L:CYBN
CYBN Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$0.14 - C$0.14
Previous CloseN/A
Volume13.54K
Average Volume (3M)0.00
Market Cap
$1.97M
Enterprise ValueN/A
Total Cash (Recent Filing)C$136.29M
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Jun 25, 2025EPS Estimate
-1.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.21
Shares Outstanding21,026,426
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$98.12Price Target Upside69988.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Cybin News
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsCYB003 has received Breakthrough Therapy Designation from the FDA, which might accelerate its path to potential approval.
Market PotentialThere is a possibility for CYB003 to achieve blockbuster status by capturing a portion of Spravato's significant market share.
ValuationEncouraging data generated so far with CYB003 in major depressive disorder, which is a large market, leads to the view that CYBN is undervalued.
Bears Say
Competitive DynamicsThere has been a moderate decrease in the price target for Cybin shares, reflecting updated estimates and competitive dynamics in the psychedelics space.
Financial PerformanceHigher operating expenses than expected were driven by increased clinical trial activity, impacting financial models.
Financial RiskPotential for dilution exists with most clinical-stage biopharma companies, including CYBN, due to ongoing trials and future capital requirements.
---
CYBN FAQ
What was Cybin’s price range in the past 12 months?
Cybin lowest stock price was C$0.14 and its highest was C$0.14 in the past 12 months.
What is Cybin’s market cap?
Cybin’s market cap is $1.97M.
When is Cybin’s upcoming earnings report date?
Cybin’s upcoming earnings report date is Jun 25, 2025 which is in 59 days.
How were Cybin’s earnings last quarter?
Cybin released its earnings results on Feb 11, 2025. The company reported -C$0.53 earnings per share for the quarter, beating the consensus estimate of -C$1.05 by C$0.52.
Is Cybin overvalued?
According to Wall Street analysts Cybin’s price is currently Undervalued.
Does Cybin pay dividends?
Cybin does not currently pay dividends.
What is Cybin’s EPS estimate?
Cybin’s EPS estimate is -1.22.
How many shares outstanding does Cybin have?
Cybin has 21,026,426 shares outstanding.
What happened to Cybin’s price movement after its last earnings report?
Cybin reported an EPS of -C$0.53 in its last earnings report, beating expectations of -C$1.05. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cybin?
Currently, no hedge funds are holding shares in TSE:CYBN
---
Company Description
Cybin
Cybin (CYBN) is a biotechnology company focused on advancing psychedelic therapeutics for mental health disorders. Operating primarily in the pharmaceutical sector, Cybin is dedicated to the research and development of psychedelic compounds, aiming to improve patient outcomes through novel drug formulations and delivery systems. The company's core services include clinical trials, drug development, and partnerships with research institutions to explore the therapeutic potential of psychedelics.
---
CYBN Stock 12 Month Forecast
Average Price Target
C$98.12
▲(69988.71% Upside)
Technical Analysis
Best Analysts Covering CYBN
1 Year
1 Year Success Rate
2/21 ratings generated profit
1 Year Average Return
-30.01%
reiterated a buy rating 2 months ago
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 9.52% of your transactions generating a profit, with an average return of -30.01% per trade.
---